Table 3. The sensitivity analyses of the study.
| Sensitivity analyses | No of studies | ORR | DCR | PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studies No. (No. of patients) | RR (95% CI) | Studies No. (No. of patients) | RR (95% CI) | Studies No. (No. of patients) | HR (95% CI) | Studies No. (No. of patients) | HR (95% CI) | |||||
| Total studies | 9 | 8 (n=1,149) | 2.16 (1.47–3.17) | 8 (n=1,149) | 1.68 (1.49–1.89) | 4 (n=686) | 0.50 (0.41–0.59) | 3 (n=605) | 0.77 (0.63–0.95) | |||
| Hensley et al. excluded | 8 | 7 (n=1,042) | 3.20 (1.85–5.52) | 7 (n=1,042) | 1.78 (1.56–2.04) | 3 (n=579) | 0.41 (0.34–0.50) | 2 (n=498) | 0.73 (0.59–0.91) | |||
| Mir (Regorafenib) et al. excluded | 8 | 7 (n=968) | 2.10 (1.42–3.10) | 7 (n=968) | 1.69 (1.47–1.93) | 4 (n=686) | 0.50 (0.41–0.59) | 3 (n=605) | 0.77 (0.63–0.95) | |||
| Mir (Pazopanib) et al. excluded | 9 | 8 (n=1,149) | 2.16 (1.47–3.17) | 8 (n=1,149) | 1.68 (1.49–1.89) | 3 (n=605) | 0.48 (0.40–0.58) | 3 (n=605) | 0.77 (0.63–0.95) | |||
| van der Graaf et al. excluded | 8 | 7 (n=780) | 1.91 (1.30–2.81) | 7 (n=780) | 1.59 (1.38–1.83) | 3 (n=317) | 0.78 (0.61–1.00) | 2 (n=236) | 0.65 (0.46–0.90) | |||
| Zhang et al. excluded | 8 | 7 (n=1,100) | 2.09 (1.42–3.09) | 7 (n=1,100) | 1.66 (1.47–1.88) | 4 (n=686) | 0.50 (0.41–0.59) | 3 (n=605) | 0.77 (0.63–0.95) | |||
| Tap et al. excluded | 8 | 7 (n=1,020) | 2.36 (1.53–3.64) | 7 (n=1,020) | 1.78 (1.55–2.04) | 3 (n=557) | 0.46 (0.38–0.50) | 2 (n=476) | 0.90 (0.71–1.13) | |||
| Hu et al. excluded | 8 | 7 (n=1,107) | 2.11 (1.40–3.20) | 7 (n=1,107) | 1.66 (1.47–1.88) | 4 (n=686) | 0.50 (0.41–0.59) | 3 (n=605) | 0.77 (0.63–0.95) | |||
| Chi et al. excluded | 8 | 7 (n=916) | 1.93 (1.31–2.85) | 7 (n=916) | 1.59 (1.40–1.79) | 4 (n=686) | 0.50 (0.41–0.59) | 3 (n=605) | 0.77 (0.63–0.95) | |||
| Liu et al. excluded | 8 | 7 (n=1,110) | 2.13 (1.45–3.13) | 7 (n=1,110) | 1.67 (1.48–1.88) | 4 (n=686) | 0.50 (0.41–0.59) | 3 (n=605) | 0.77 (0.63–0.95) | |||
ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; RR, risk ratio; HR, hazard ratio; CI, confidence interval.